Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Core Insights - Structure Therapeutics is advancing its clinical development programs for aleniglipron, an oral small molecule GLP-1 receptor agonist, with topline data readouts expected by the end of 2025 [1][2] - The company is also initiating a Phase 1 study for ACCG-2671, an oral small molecule amylin receptor agonist, anticipated by year-end 2025 [1][2] - As of June 30, 2025, the company reported a strong financial position with cash, cash equivalents, and short-term investments totaling $786.5 million, expected to fund operations through at least 2027 [1][9] Clinical Development - The ACCESS and ACCESS II studies for aleniglipron are fully enrolled, with approximately 220 and 80 adults participating, respectively, and are designed to evaluate various doses and long-term effects [3][4] - Additional studies for aleniglipron include an open-label extension and an extension of ACCESS II to gather more long-term data on safety and efficacy [4][5] - The company is also developing a pipeline of oral small molecule therapeutics targeting obesity and related metabolic diseases, focusing on combinability and long-term weight loss maintenance [2][10] Financial Performance - Research and Development (R&D) expenses for Q2 2025 were $54.7 million, a significant increase from $22.1 million in Q2 2024, driven by clinical trial costs and pre-clinical research [10][11] - General and Administrative (G&A) expenses rose to $15.7 million in Q2 2025 from $11.3 million in Q2 2024, reflecting increased personnel-related expenses [11] - The net loss for Q2 2025 was $61.7 million, compared to a net loss of $26.0 million in Q2 2024, with non-cash share-based compensation contributing to the loss [12][16] Pipeline and Future Studies - Structure Therapeutics is planning to initiate several new studies, including a Phase 2 body composition study and a Phase 2 study in patients with type 2 diabetes mellitus (T2DM), both expected to start in late 2025 [10][12] - The company is also advancing its oral small molecule programs targeting various receptors, including GIPR and GCGR, to treat obesity and related diseases [10][12] - ACCG-2671 has shown promising preclinical results, demonstrating significant body weight reductions in diet-induced obese rats and potential for combination therapy with semaglutide [10][12]